Bristol-Myers Squibb Award Goes to Folkman

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

NEW YORK--Judah Folkman, MD, who first theorized that tumors form and metastasize by means of angiogenesis, is the winner of the 18th annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research.

NEW YORK--Judah Folkman, MD, who first theorized that tumors formand metastasize by means of angiogenesis, is the winner of the18th annual Bristol-Myers Squibb Award for Distinguished Achievementin Cancer Research.

In 1971, Dr. Folkman reported the isolation of the first angiogenicfactor, a substance that induces blood vessel growth. In 1984,he and his colleagues Yuen Shing and Michael Klagsbrun purifiedthe first tumor-derived angiogenic factor, and Dr. Folkman laterdiscovered the first angiogenesis inhibitor.

Dr. Folkman is Julia Dyckman Andrus Professor of Pediatric Surgery,Harvard Medical School, and director of the Surgical ResearchLaboratory, Children's Hospital, Boston.

The company also announced the recipients of the 1995 Bristol-MyersSquibb Unrestricted Cancer Research Grants--Indiana UniversityCancer Center and the National Cancer Institute, Milan.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content